Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 18 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase III Chemotherapy with AMSA vs Immunotherapy with Poly-ICLC as Maintenance Therapy for Acute Nonlymphocytic Leukemia in Second Remission

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				over 18								UMCC-8038


2.		Phase I-II Immunotherapy with Poly ICLC for Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				no age specified								MDA-M-8002


3.		Phase I/II Immunotherapy with Poly-ICLC for Recurrent Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				no age specified				NCI				EST-PC-680


4.		Phase II Immunotherapy with Stabilized Poly-IC (Poly-ICLC) in the Treatment of Refractory Pediatric Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				under 18								NCI-79-C-23 NCI-POB-7803


5.		Phase II Study of Human Lymphoblastoid Interferon vs Stabilized Poly-IC (Poly-ICLC) for Acute Myelocytic Leukemia, CLL, and Various Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18								NCI-79-C-80 NCI-POB-7901, UMCC-7914


6.		Phase II Immunotherapy with Stabilized Poly-IC (Poly-ICLC) for Previously Treated Children with Acute Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				under 21				NCI				CCG-082


7.		Phase II Immunotherapy with Poly ICLC for Refractory Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified								MDA-MBDT-8027


8.		Phase II Immunotherapy with Poly-ICLC for Children with Metastatic Neuroblastoma Refractory to Standard Treatment

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				under 21				NCI				CCG-082A

Last Modified: 4/26/2007


9.		Phase II Immunotherapy with the Interferon Inducer Poly ICLC in Patients with Unresectable Renal Cell Cancer (Summary Last Modified 07/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				EST-PA-884 EST-P-A884

Last Modified: 8/1/1988


10.		Phase II Immunotherapy with the Interferon Inducer Poly ICLC in Patients with Relapsed Lymphoma, Hodgkin's Disease, or Cutaneous T-Cell Lymphoma (Summary Last Modified 08/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				EST-PB-484 EST-P-B484

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute